EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION

Authors
LINK H BRUNE T HUBNER G DIEDRICH H FREUND M STOLL M PEEST D EBELL W BETTONI C OSTER W NICOLAY U HEINRICHS H
Citation
H. Link et al., EFFECT OF RECOMBINANT-HUMAN-ERYTHROPOIETIN AFTER ALLOGENEIC BONE-MARROW TRANSPLANTATION, Annals of hematology, 67(4), 1993, pp. 169-173
Citations number
32
Categorie Soggetti
Hematology
Journal title
Annals of hematology → ACNP
ISSN journal
09395555
Volume
67
Issue
4
Year of publication
1993
Pages
169 - 173
Database
ISI
SICI code
0939-5555(1993)67:4<169:EORAAB>2.0.ZU;2-C
Abstract
The hematologic effects of recombinant human erythropoietin after allo geneic bone marrow transplantation (BMT) were studied. Nineteen patien ts received 150 U/kg/day of C127 mouse-cell-derived recombinant human erythropoietin (rHu EPO) as a daily continuous intravenous infusion un til hematocrit exceeded 35%. These data were compared with a treatment -matched historical control group of 43 patients. RHu EPO-treated pati ents recovered erythropoiesis more rapidly and became independent from erythrocyte transfusions after a median of 17 days, which was 7 days earlier than the control patients.